The content of the article continued
What do you think about stopping some important vaccine attempts this week?
“I would say that something like this is relatively common. When we look at trials that may involve up to 50,000 people, I would not say that it is too unique to have the potential to stop a process in which due to some complication or some kind of disease, you need to do additional investigations.
“Is there scientific rigor in each issue given the urgency of trying to get something out and the speed with which we are going through this process of developing some of the key vaccine candidates?”
Is it possible to have an annual or one-time vaccine or can there be several versions worldwide?
“A lot of these questions depend on the type of vaccine that’s on offer, and whether it’s a more universal approach to something that’s actually strictly for (COVID-19) … It also depends on the type of vaccine you’re developing.” It may not be for all age groups and may only be for, for example, adults aged 18 to 40 …
“Although we have several candidates (vaccine), not all of them will reach final approval. So having a few shots on the net is important for a number of reasons for many of these variables … We don’t really know the trajectory of what COVID-19 will look like and what COVID-20 will look like … ”
Is it possible that treatment is the best option or will this pandemic end with a vaccine?
“I have no doubt that this will eventually end in a vaccine. I think the important part to understand here is that developing a vaccine is not just something … One thing I can say is that to see the development process that works so fast with this number candidates (vaccine) is unseen. This is a truly unique time in history at the scientific level. “